Dalteparin vs. vitamin K antagonist (VKA) for the prevention of recurrent venous thromboembolism (VTE) in cancer patients with renal insufficiency: A patient level pharmacoeconomic analysis in three European countries

Date

09 Oct 2016

Session

Poster display

Presenters

Lesley Shane

Citation

Annals of Oncology (2016) 27 (6): 351-358. 10.1093/annonc/mdw377

Authors

L. Shane1, G. Dranitsaris2, S. Woodruff3, J. Galanaud4, G. Stemer5, P. Debourdeau6, B. Valtier7, L. Burgers8

Author affiliations

  • 1 Global Health And Value, Pfizer Inc., 10017-5755 - New York/US
  • 2 Outcomes Research, Augmentium Pharma Consulting Inc, m4k 1n2 - Toronto/CA
  • 3 Medical, Pfizer Inc., 10017-5755 - New York/US
  • 4 Department Of Internal Medicine, Montpellier University Hospital, Montpellier/FR
  • 5 Pharmacy, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna/AT
  • 6 Oncology, Hopital Desgenettes, Lyon/FR
  • 7 Medical, Pfizer France, 10017-5755 - Paris/FR
  • 8 Public Affairs And Policy, Pfizer BV, Capelle a/d Ijssel/NL
More

Resources

Background

In a randomized trial (i.e. CLOT) which evaluated extended duration prophylaxis of recurrent VTE in cancer patients (Lee et al, 2003), dalteparin reduced the relative risk of recurrent VTE by 52% compared to oral VKA therapy (P = 0.002). A recent subgroup analysis in patients with moderate to severe renal impairment at randomization also revealed lower absolute VTE rates with dalteparin (3% vs. 17%; p = 0.011). A patient level pharmacoeconomic analysis was conducted to evaluate these indications from the French, Austrian and Dutch health care system perspectives.

Methods

Resource utilization data contained within the database was extracted and converted into direct cost estimates for each country. Univariate analysis was used to compare the total cost of therapy between patients randomized to dalteparin or VKA therapy for each country. To estimate the cost per quality adjusted life year (QALY) gained with dalteparin, health state utilities were measured in 24 members of the general public using the Time Trade-Off technique.

Results

When all of the cost components were combined for the entire population (n = 676), the dalteparin group had significantly higher mean overall costs than the VKA group in each of the respective countries (Table). However, the preference assessment revealed that 21 of 24 respondents (88%) selected dalteparin over VKA with an associated gain of 0.14 (95%CI: 0.10 – 0.18) QALYs, resulting in favourable cost effectiveness ratios.

Country* Dalteparin VKA Cost / QALY
France €2,267 (80) €1,352 (94) €6,600
Austria €2,687 (81) €2,012 (102) €4,900
Netherlands €2,376 (81) €1,724 (102) €4,697

*p 

Conclusions

Extended duration prophylaxis with dalteparin is a clinically and cost effective alternative to VKA for the prevention of recurrent VTEs in patients with cancer, especially in those with renal impairment.

Clinical trial identification

Legal entity responsible for the study

Pfizer Inc

Funding

Pfizer Inc

Disclosure

L. Shane: Employed by the sponsor; Pfizer Inc. G. Dranitsaris: Consultant to Pfizer Inc. S. Woodruff, B. Valtier, L. Burgers: Employed by Pfizer Inc. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings